Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Improving CAR T-Cell Therapy in Multiple Myeloma

July 2nd 2024

Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.

Belantamab Mafodotin–Based Combo Boosts PFS in Difficult-to-Treat R/R Myeloma Subgroups

July 1st 2024

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

June 28th 2024

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma

June 27th 2024

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies

June 27th 2024

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.

Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

June 26th 2024

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Arnulf on Patient Factors and Biomarkers Impacting PFS With Ide-Cel in R/R Myeloma

June 25th 2024

Bertrand Arnulf, MD, PhD, discusses patient factors and pharmacodynamic biomarkers that impact survival outcomes with ide-cel in multiple myeloma.

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

June 25th 2024

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.

Linvoseltamab Displays Durable Efficacy in Relapsed/Refractory Multiple Myeloma

June 25th 2024

Linvoseltamab demonstrated durable efficacy with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

Dr Siegel on Real-World Outcomes With Tandem Transplant in Newly Diagnosed Myeloma

June 25th 2024

David Samuel Dicapua Siegel, MD, discusses real-world outcomes with tandem transplantation in newly diagnosed multiple myeloma.

Dr McCarthy on Neutrophil-Mediated Immunosuppression in Multiple Myeloma

June 24th 2024

Philip McCarthy, MD, discusses findings from an investigation, assessing the impact of neutrophils within the tumor microenvironment of multiple myeloma.

Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma

June 24th 2024

Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.

Dr Biran on Current Unmet Needs in Relapsed/Refractory Multiple Myeloma

June 18th 2024

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

Dr Mateos on Belantamab Mafodotin Plus Bortezomib/Dexamethasone in R/R Myeloma

June 18th 2024

María-Victoria Mateos, MD, PhD, discusses findings for belantamab mafodotin plus bortezomib and dexamethasone.

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple Myeloma

June 17th 2024

Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

June 16th 2024

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

June 14th 2024

Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden

June 14th 2024

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.